XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Segment Information (Details)
3 Months Ended
Mar. 31, 2024
USD ($)
segment
Mar. 31, 2023
USD ($)
Statements    
Number of operating segments | segment 2  
Results of operations by reportable segment    
Net sales $ 1,388,806 $ 2,517,972
Cost of goods sold 331,831 550,742
Selling, general and administrative expenses 2,711,456 2,130,639
Research and development expenses 1,555,953 319,093
Depreciation and amortization expense 717,839 826,795
Change in fair value of derivative liability (1,734,000)  
Interest income (151,819) (66,317)
Interest expense 120,209 142,167
Net (loss) and income $ (2,162,663) (1,385,147)
Operating segments    
Statements    
Number of operating segments | segment 2  
Corporate    
Results of operations by reportable segment    
Selling, general and administrative expenses $ 1,530,785 1,209,921
Change in fair value of derivative liability (1,734,000)  
Interest income (151,819) (66,317)
Interest expense 120,209 142,167
Net (loss) and income 234,825 (1,285,771)
Prescription Medications | Operating segments    
Results of operations by reportable segment    
Net sales 613,095 1,506,278
Cost of goods sold 75,356 174,270
Selling, general and administrative expenses 677,896 496,847
Research and development expenses 1,555,953 265,216
Depreciation and amortization expense 500,305 575,470
Net (loss) and income (2,196,415) (5,525)
Medical Devices | Operating segments    
Results of operations by reportable segment    
Net sales 775,711 1,011,694
Cost of goods sold 256,475 376,472
Selling, general and administrative expenses 502,775 423,871
Research and development expenses   53,877
Depreciation and amortization expense 217,534 251,325
Net (loss) and income $ (201,073) $ (93,851)